Previous close | 1.4900 |
Open | 1.5000 |
Bid | 1.4200 x 100 |
Ask | 1.5300 x 100 |
Day's range | 1.4500 - 1.5000 |
52-week range | 1.0500 - 3.9700 |
Volume | |
Avg. volume | 196,981 |
Market cap | 38.741M |
Beta (5Y monthly) | 1.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2700 |
Earnings date | 15 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.83 |
NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Pag
ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNew partnership with Densitas provides end-to-end breast health solution ensuring every aspect of a woman’s breast health journey is addressedEnhanced ProFound Detection Workstation features streamline mammogram interpretation for radiologists NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASD
Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluationExpands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection so